Dorsey & Whitney Trust CO LLC Has $389,000 Stock Position in GSK plc (NYSE:GSK)

Dorsey & Whitney Trust CO LLC raised its holdings in GSK plc (NYSE:GSK) by 2.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 11,506 shares of the pharmaceutical company’s stock after acquiring an additional 278 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in GSK were worth $389,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FMR LLC increased its position in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC increased its position in GSK by 1.4% in the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock valued at $637,061,000 after acquiring an additional 259,867 shares during the period. Primecap Management Co. CA boosted its stake in shares of GSK by 2.4% in the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after purchasing an additional 342,365 shares during the last quarter. Equity Investment Corp boosted its stake in shares of GSK by 13.3% in the 4th quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock valued at $134,014,000 after purchasing an additional 466,327 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC boosted its stake in shares of GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after purchasing an additional 833,080 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Up 0.9 %

Shares of NYSE GSK opened at $40.41 on Tuesday. The firm has a market cap of $83.74 billion, a PE ratio of 25.41, a P/E/G ratio of 1.12 and a beta of 0.58. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93. The company’s fifty day simple moving average is $35.61 and its 200 day simple moving average is $37.13. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, sell-side analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 3.89%. GSK’s dividend payout ratio is presently 98.74%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on GSK shares. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.